Skip to content

Effect of Total Knee Arthroplasty on Sarcopenia in Patients With Osteoarthritis in the Knee

Effect of Total Knee Arthroplasty on Sarcopenia in Patients With Osteoarthritis in the Knee

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03579329
Acronym
Sarcopenia
Enrollment
58
Registered
2018-07-06
Start date
2020-04-30
Completion date
2022-02-02
Last updated
2022-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Knee, Sarcopenia

Keywords

sarcopenia, Osteoarthritis, Total Knee Arthroplasty

Brief summary

Sarcopenia is a wasting disease with the locomotion system in the aged population. It is defined as the decline in muscle mass (lean body mass) and strength with the advance of age. The prevalence of sarcopenia increases with age, reaching an astounding 50% among the population aged over 75 in the United States. Sarcopenia is often associated with frailty, falls, and disability. Studies have found sarcopenia can be a predicting risk factor for fractures in the elderly. In addition, sarcopenia predicted a higher chance of mortality in nursing homes.

Detailed description

Notably, sarcopenia often accompanies with osteoarthritis (OA). However, the relationship between sarcopenia and OA is still unclear. One understanding is that sarcopenia and OA and co-existing conditions. One study identified sarcopenia as one of the risk factors of OA. There is also a study which speculated that OA may inhibit the progression of sarcopenia since they observed OA patients had higher BMP4-positive tissues, which indicated presence of satellites cells that may increase muscle regeneration capabilities. However, more studies suggested that OA may contribute to the development of sarcopenia among the elderly. First, it is observed that the prevalence of sarcopenia among OA patients is higher than among the normal population. Further, cross-sectional studies demonstrated that hip or knee OA are associated with declines in muscle mass and muscle strength. Most interestingly, female patients with knee OA had declined lean body mass in their lower limbs, but not in their upper limbs or trunks. Major risk factors of sarcopenia include malnutrition and lack of physical exercise. Therefore, diet supplementation and exercise potentially provide means to alleviate sarcopenia. Studies have demonstrated that strength training in the elderly can improve sarcopenia by increasing muscle strength, mass, power and quality. Exercise habit in middle age could prevent sarcopenia in elder age, maintaining better scores in grip strength, gait speed, and one-leg standing time. Possible molecular mechanism of exercise on sarcopenia is the upregulated nuclear factor-erythroid 2 p45-related factor 2 (Nrf2)-mediated antioxidant response cascade in skeletal muscle, which protected the muscle from oxygen species-mediated toxicity. OA patients often adopt a sedentary life style to avoid joint pain and stiffness, which probably triggers the dysfunction of Nrf2 -mediated antioxidant response cascade, eventually leading to skeletal muscle atrophy. With the ultimate solution, total knee anthroplasty (TKA), patients with knee OA gradually regain their mobility and greatly increase their social and physical activities. Therefore, one can expect to see improved sarcopenia in patients with knee OA after TKA.

Interventions

PROCEDURETotal Knee Arthroplasty

Effect of Total Knee Arthroplasty on Sarcopenia in Patients with Osteoarthritis in the Knee

Sponsors

Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male and Female aged over 18 wirh end stage knee OA * Scheduled for TKA * Agree to provide written consent

Exclusion criteria

* History of alcoholism or drug abuse * Pregnancy and breast-feeding * Presence of serious pathologies * Steroid-based systemic therapy in progress or interrupted since less than 1 month * With significant hematologic diseases

Design outcomes

Primary

MeasureTime frameDescription
International Physical Activity Questionnaire (IPAQ)one yearQuestionnaire
DXA scanone yearLean Muscle Mass Index

Secondary

MeasureTime frameDescription
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)one yearQuestionnaire
Self-Rated 12one yearQuestionnaire

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 16, 2026